Huntington’s Disease Treatment was estimated at USD 380.3 million in 2022 and is poised to reach at 2045.3 million in 2030 anticipated to expand at a compound annual growth rate approx. CAGR of 23.4% for the forecast period of 2023-2030.
Ingrezza’s projected label expansion for the treatment of chorea linked to Huntington's disease (HD), the high prevalence of HD in western nations, and a robust product pipeline of disease-modifying medicines are predicted to be key market drivers. HD has a frequency of 5.8 per 100,000 individuals in North America, affecting around 30,000 people. HD in children makes up just 5% to 10% of all cases, which is a significant decrease. Up to 10 out of every 100,000 people in Europe are impacted. HD is a neurological disorder that worsens with time and is brought on by CAG expansions in the Huntingtin (Htt) gene. One in every 10,000 Americans is impacted by it. Less than 35 CAG repeats are seen in healthy individuals, but 36 to 200 CAG expansions are found in HD patients. Due to differences in case ascertainment and diagnostic criteria, the prevalence varies between regions by a factor of more than 10. While Europe, North America, and Australia have greater prevalences, the Asian population has continuously had a lower prevalence. The goal of a number of small molecules now in clinical development is to employ immunomodulatory medications to target the hyperactive immune system in HD. However, because various treatments either failed to show effectiveness or were linked to considerable toxicity, medication research for HD has encountered major challenges. F. Hoffmann-La Roche Ltd. stopped administering tominersen in the phase III Generation HD1 trial for manifest HD in March 2021. The result was reached after a deliberate, unblinded analysis of phase III study data by the Independent Data Monitoring Committee (iDMC). No fresh or emerging safety signals for Tominersen were found when this data was analysed.
DRIVERS
Rising prevalence & Technological developments.
Positive regulatory environment.
Huntington's disease is an uncommon hereditary condition, but it is becoming more common everywhere. The need for efficient therapies is rising along with the number of patients. New insights into the disease's fundamental processes have been made possible by developments in genetics, neurology, and medical research. Innovative therapeutic modalities have been made possible by this information. Regulatory bodies have expressed a greater desire to hasten the approval of medicines for Huntington's disease. Pharmaceutical businesses have been inspired to spend money on R&D because of this.
RESTRAIN
Pathology of a complicated illness & Limited possibilities for treatment.
Huntington's disease is a neurological ailment with a complex pathology. It is still difficult to create tailored medicines that successfully treat both symptoms and underlying causes. Huntington's illness is currently incurable. The existing therapies concentrate on symptom management and patient quality of life enhancement. Novel therapeutic methods are required because there are few available therapy choices.
OPPORTUNITY
Gene therapies & Neuroprotective strategies.
By focusing on the faulty huntingtin gene that causes the ailment, gene editing technologies like CRISPR-Cas9 show promise for treating Huntington's disease. There is a chance for major progress in the treatment of this condition because of clinical studies examining gene-based treatments. Research into these techniques tries to halt the course of illness and maintain brain function. The chance for efficient disease management lies in the discovery of possible neuroprotective substances or therapies.
CHALLENGES
High expenses for research and development & Recruitment for clinical studies.
There are high costs associated with developing novel therapies for Huntington's disease, including research, clinical trials, and regulatory compliance. The pharmaceutical business and academics are both challenged by the high expenses involved in medication development. Huntington's illness has serious ethical ramifications because it is a hereditary disorder. Genetic medicines are being developed and put into use, which raises ethical questions about gene editing, privacy, and genetic prejudice. Given the rarity of Huntington's disease and the stringent qualifying requirements, it might be difficult to find enough people for clinical trials. For the purpose of producing accurate data, it is essential to provide strong and diversified trial populations.
It's possible that the conflict will take money and people away from attempts to advance science. Funding that may have been used for research projects, such as those pertaining to Huntington's disease, could instead be used for critical humanitarian or military requirements. Patients and healthcare workers are relocated. People are frequently displaced as a result of conflict, including patients and healthcare workers. Huntington's disease patients could be compelled to leave their homes and communities, which would interfere with their access to supportive networks and specialised care. Similar to other professions, those involved in healthcare may be uprooted or forced to leave conflict-affected areas, leaving the industry short of qualified specialists. psychological effects on clients and staff People with Huntington's disease and those who care for them may have psychological effects as a result of the war and its accompanying pressures. Even though managing a complicated neurological ailment like Huntington's disease can be difficult, conflict's additional stress and trauma can worsen symptoms and impair general wellbeing.
IMPACT OF ONGOING RECESSION
Healthcare spending and access to medical services may decline during economic downturns. This may have an effect on those who have Huntington's disease, making it more difficult for them to pay for important therapies, drugs, and treatments. Reduced access to healthcare services may lead to delayed diagnoses, ineffective symptom treatment, and worse patient outcomes overall. People may be less eager or financially able to take part in clinical studies during a recession. Clinical trials are essential for evaluating novel therapies and developing the study of Huntington's disease. A decline in clinical trial enrolment may cause prospective medicines to develop more slowly and take longer to reach patients.
Governments may alter healthcare policies in reaction to a recession by making budget cuts, reducing reimbursements, or otherwise when it comes to insurance. These modifications may affect the accessibility and cost of therapies for Huntington's disease, making it more difficult for individuals to get the care they need.
By Treatment
Symptomatic Treatment
Disease-modifying Therapies
By End Use
Hospital Pharmacy
Retail Pharmacy
E-commerce
.png)
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin American
North America:
In terms of revenue, the market for treating Huntington's disease in 2022 will be dominated by North America (40.79%). This expansion is brought on by the high disease burden, rising healthcare costs, technological developments, proactive government measures, and growing patient knowledge of Huntington's disease treatment options. By releasing symptom management medications, major firms like H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. assist in market expansion.
Asia Pacific:
Due to increased product penetration, untapped potential, and the rising incidence of the condition in emerging nations throughout the projected period, the Asia-Pacific market for the treatment of Huntington's disease is anticipated to see a substantial CAGR. The region's market is anticipated to rise as a result of an increase in the number of government programmes aimed at enhancing population health. The market for treating Huntington's illness is, however, crowded, which could prevent its expansion in this area. For instance, Indian generic producers Lupin Ltd. and Aurobind were the targets of a patent litigation brought by Teva Pharmaceutical Industries Ltd. in July 2021.
The major Key Players are Neurocrine Biosciences, NeuExcell Therapeutics Inc, H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc., Hetero, Lupin, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd, and others.
Neurocrine Biosciences:
In May 2023, a phase 3 trial using the medication valbenazine from Neurocrine Biosciences revealed that it significantly improved the treatment of chorea linked to Huntington's disease. Throughout the projection period, the predicted approval and subsequent launch of comparable medications are likely to fuel market expansion.
NeuExcell Therapeutics Inc:
In order to explore gene therapy for treating HD patients, NeuExcell Therapeutics Inc. partnered with Spark Therapeutics, Inc., a subsidiary of F. Hoffmann-La Roche Ltd., in September 2021. NeuExcell Therapeutics is qualified to collect up-front licence fees, R&D and sales milestone payments of up to roughly USD 190 million, and extra product royalties under the terms of the contract.
| Report Attributes | Details |
| Market Size in 2022 | US$ 380.3 Mn |
| Market Size by 2030 | US$ 2045.3 Mn |
| CAGR | CAGR of 23.4% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Treatment (Symptomatic Treatment, Disease-modifying Therapies) • By End Use (Hospital Pharmacy, Retail Pharmacy, E-commerce) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Neurocrine Biosciences, NeuExcell Therapeutics Inc, H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc., Hetero, Lupin, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd |
| Key Drivers | • Rising prevalence & Technological developments. • Positive regulatory environment. |
| Market Opportunities | • Gene therapies & Neuroprotective strategies. |
Ans: The CAGR Growth rate of Huntington’s Disease Treatment Market is approx. CAGR 23.4% for the forecast period of 2023-2030.
Ans: The projected market size of Huntington’s Disease Treatment Market at USD 380.3 million in 2022 and is poised to reach at 2045.3 million in 2030.
Ans: The major Key Players are Neurocrine Biosciences, NeuExcell Therapeutics Inc, H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc., Hetero, Lupin, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd, and others.
Ans: The market for treating Huntington's disease was dominated by symptomatic therapy in 2022, with a share of 100%. This can be attributed to the availability of symptom management medications like Austedo, Xenazine, and Tetrabenazine as generic medicines, the introduction of new pharmaceuticals, and R&D projects involving the development of symptomatic remedies, including products like Ingrezza, SRX246, and SOM3355, among others.
Ans: The prevalence of Huntington's disease in developed nations and the market's strong product pipeline are two of the main drivers of market expansion.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Huntington’s Disease Treatment Market, By Treatment
8.1 Symptomatic Treatment
8.2 Disease-modifying Therapies
9. Huntington’s Disease Treatment Market, By End Use
9.1 Hospital Pharmacy
9.2 Retail Pharmacy
9.3 E-commerce
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 North America Huntington’s Disease Treatment Market, by country
10.2.2North America Huntington’s Disease Treatment Market by Treatment
10.2.3 North America Huntington’s Disease Treatment Market by End Use
10.2.4 USA
10.2.4.1 USA Huntington’s Disease Treatment Market by Treatment
10.2.4.2 USA Huntington’s Disease Treatment Market by End Use
10.2.7 Canada
10.2.7.1 Canada Huntington’s Disease Treatment Market by Treatment
10.2.7.2 Canada Huntington’s Disease Treatment Market by End Use
10.2.8 Mexico
10.2.8.1 Mexico Huntington’s Disease Treatment Market by Treatment
10.2.8.2 Mexico Huntington’s Disease Treatment Market by End Use
10.3 Europe
10.3.1 Europe Huntington’s Disease Treatment Market by country
1.3.3.2 Europe Huntington’s Disease Treatment Market by Treatment
10.3.3 Europe Huntington’s Disease Treatment Market by End Use
10.3.6 Germany
10.3.6.1 Germany Huntington’s Disease Treatment Market by Treatment
10.3.6.2 Germany Huntington’s Disease Treatment Market by End Use
10.3.7 UK
10.3.7.1 UK Huntington’s Disease Treatment Market by Treatment
10.3.7.2 UK Huntington’s Disease Treatment Market by End Use
10.3.8 France
10.3.8.1 France Huntington’s Disease Treatment Market by Treatment
10.3.8.2 France Huntington’s Disease Treatment Market by End Use
10.3.9 Italy
10.3.9.1 Italy Huntington’s Disease Treatment Market by Treatment
10.3.9.2 Italy Huntington’s Disease Treatment Market by End Use
10.3.10 Spain
10.3.10.1 Spain Huntington’s Disease Treatment Market by Treatment
10.3.10.2 Spain Huntington’s Disease Treatment Market by End Use
10.3.11 The Netherlands
10.3.11.1 Netherlands Huntington’s Disease Treatment Market by Treatment
10.3.11.2 Netherlands Huntington’s Disease Treatment Market by End Use
10.3.12 Rest of Europe
10.3.12.1 Rest of Europe Huntington’s Disease Treatment Market by Treatment
10.3.12.2 Rest of Europe Huntington’s Disease Treatment Market by End Use
10.4 Asia-Pacific
10.4.1 Asia Pacific Huntington’s Disease Treatment Market by country
10.4.2 Asia Pacific Huntington’s Disease Treatment Market by Treatment
10.4.3 Asia Pacific Huntington’s Disease Treatment Market by End Use
10.4.6 Japan
10.4.6.1 Japan Huntington’s Disease Treatment Market by Treatment
10.4.6.2 Japan Huntington’s Disease Treatment Market by End Use
10.4.7 South Korea
10.4.7.1 South Korea Huntington’s Disease Treatment Market by Treatment
10.4.7.2 South Korea Huntington’s Disease Treatment Market by End Use
10.4.8 China
10.4.8.1 China Huntington’s Disease Treatment Market by Treatment
10.4.8.2 China Huntington’s Disease Treatment Market by End Use
10.4.9 India
10.4.9.1 India Huntington’s Disease Treatment Market by Treatment
10.4.9.2 India Huntington’s Disease Treatment Market by End Use
10.4.10 Australia
10.4.10.1 Australia Huntington’s Disease Treatment Market by Treatment
10.4.10.2 Australia Huntington’s Disease Treatment Market by End Use
10.4.11 Rest of Asia-Pacific
10.4.11.1 APAC Huntington’s Disease Treatment Market by Treatment
10.4.11.2 APAC Huntington’s Disease Treatment Market by End Use
10.5 The Middle East & Africa
10.5.1 The Middle East & Africa Huntington’s Disease Treatment Market by country
10.5.2 The Middle East & Africa Huntington’s Disease Treatment Market by Treatment
10.5.3 The Middle East & Africa Huntington’s Disease Treatment Market by End Use
10.5.6 Israel
10.5.6.1 Israel Huntington’s Disease Treatment Market by Treatment
10.5.6.2 Israel Huntington’s Disease Treatment Market by End Use
10.5.7 UAE
10.5.7.1 UAE Huntington’s Disease Treatment Market by Treatment
10.5.7.2 UAE Huntington’s Disease Treatment Market by End Use
10.5.8 South Africa
10.5.8.1 South Africa Huntington’s Disease Treatment Market by Treatment
10.5.8.2 South Africa Huntington’s Disease Treatment Market by End Use
10.5.9 Rest of Middle East & Africa
10.5.9.1 Rest of Middle East & Asia Huntington’s Disease Treatment Market by Treatment
10.5.9.2 Rest of Middle East & Asia Huntington’s Disease Treatment Market by End Use
10.6 Latin America
10.6.1 Latin America Huntington’s Disease Treatment Market by country
10.6.2 Latin America Huntington’s Disease Treatment Market by Treatment
10.6.3 Latin America Huntington’s Disease Treatment Market by End Use
10.6.6 Brazil
10.6.6.1 Brazil Huntington’s Disease Treatment Market by Treatment
10.6.6.2 Brazil Africa Huntington’s Disease Treatment Market by End Use
10.6.7 Argentina
10.6.7.1 Argentina Huntington’s Disease Treatment Market by Treatment
10.6.7.2 Argentina Huntington’s Disease Treatment Market by End Use
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Huntington’s Disease Treatment Market by Treatment
10.6.8.2 Rest of Latin America Huntington’s Disease Treatment Market by End Use
11 Company profile
11.1 Sun Pharmaceutical Industries Ltd
11.1.1 Market Overview
11.1.2 Financials
11.1.3 Treatment/Services/Offerings
11.1.4 SWOT Analysis
11.1.5 The SNS View
11.2 Dr. Reddy’s Laboratories Ltd.
11.2.1 Market Overview
11.2.2 Financials
11.2.3 Treatment/Services/Offerings
11.2.4 SWOT Analysis
11.2.5 The SNS View
11.3 Hikma Pharmaceuticals PLC,
11.3.1 Market Overview
11.3.2 Financials
11.3.3 Treatment/Services/Offerings
11.3.4 SWOT Analysis
11.3.5 The SNS View
11.4 Lupin
11.4.1 Market Overview
11.4.2 Financials
11.4.3 Treatment/Services/Offerings
11.4.4 SWOT Analysis
11.4.5 The SNS View
11.5 Hetero,
11.5.1 Market Overview
11.5.2 Financials
11.5.3 Treatment/Services/Offerings
11.5.4 SWOT Analysis
11.5.5 The SNS View
11.6 Bausch Health Companies Inc.
11.6.1 Market Overview
11.6.2 Financials
11.6.3 Treatment/Services/Offerings
11.6.4 SWOT Analysis
11.6.5 The SNS View
11.7 Teva Pharmaceutical Industries Ltd,
11.7.1 Market Overview
11.7.2 Financials
11.7.3 Treatment/Services/Offerings
11.7.4 SWOT Analysis
11.7.5 The SNS View
11.8 H. Lundbeck A/S,
11.8.1 Market Overview
11.8.2 Financials
11.8.3 Treatment/Services/Offerings
11.8.4 SWOT Analysis
11.8.5 The SNS View
11.9 NeuExcell Therapeutics Inc,
11.9.1 Market Overview
11.9.2 Financials
11.9.3 Treatment/Services/Offerings
11.9.4 SWOT Analysis
11.9.5 The SNS View
11.10 Neurocrine Biosciences.
11.10.1 Market Overview
11.10.2 Financials
11.10.3 Treatment/Services/Offerings
11.10.4 SWOT Analysis
11.10.5 The SNS View
12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share analysis
12.3 Recent Developments
13. Use Case and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Medical Waste Containers Market Size was valued at USD 1.89 billion in 2022 and is expected to reach USD 3.02 billion by 2030, and grow at a CAGR of 6.0% over the forecast period 2023-2030.
The Low-Pressure Liquid Chromatography Market Size was valued at USD 6.77 billion in 2022, and is expected to reach USD 12.07 billion by 2030, and grow at a CAGR of 7.5% over the forecast period 2023-2030.
The Bovine Mastitis Market size was USD 0.61 Billion in 2022 and is expected to Reach USD 0.97 Billion by 2030 and grow at a CAGR of 6.1% over the forecast period of 2023-2030.
The 3D Printing Medical Device Software Market Size was valued at USD 11.29 billion in 2023 and is expected to reach USD 41.08 billion by 2031 and grow at a CAGR of 17.86% over the forecast period 2024-2031
The Health IT Security Market Size was valued at USD 12.35 billion in 2022, and is expected to reach USD 19.10 billion by 2030, and grow at a CAGR of 15.6% over the forecast period 2023-2030.
The Dermatology Drugs Market size was USD 41.67 Billion in 2023 and is expected to Reach USD 78.86 Billion by 2031 and grow at a CAGR of 8.3% over the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
